Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests best shot for stubborn neck pain

NCT ID NCT07547605

Symptom relief Sponsor: University of Kyrenia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests three types of injections for people with chronic neck and shoulder muscle pain caused by trigger points. It compares platelet-rich plasma (PRP), a mix of PRP and steroid, and steroid alone to see which works best. 150 adults aged 18-65 with a single active trigger point will be followed for 6 months. The goal is to find the most effective treatment for reducing pain and improving movement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years * Presentation to the Orthopedics and Traumatology outpatient clinic with neck and/or shoulder pain * Diagnosis of upper trapezius myofascial pain syndrome based on Simons and Travell criteria, including: * Presence of a taut band * Local tenderness * Referred pain pattern * Local twitch response * Presence of a single active trigger point in the upper trapezius muscle * Symptom duration ≥ 4 weeks * Pain intensity ≥ 4 on the visual analog scale (VAS) * Inadequate response to at least 4 weeks of conservative treatment (physical therapy and/or oral analgesics) * Ability to provide written informed consent Exclusion Criteria: * Presence of multiple active trigger points * Diagnosis of fibromyalgia according to ACR 2010 criteria * Cervical radiculopathy or myelopathy * Trigger point injection in the same region within the past 3 months * Coagulopathy or current anticoagulant or antiplatelet therapy * Known allergy or contraindication to corticosteroids, local anesthetics, or PRP components * Active infection (systemic or local) * Pregnancy or lactation * Thrombocytopenia (platelet count \< 100,000/µL) * Malignancy * Inability to cooperate or provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myofascial pain dysfunction syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fibromyalgia myofascial pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myofascial pain dysfunction syndrome Trigger point in trapezius muscle Trigger points, myofascial

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dr. Suat Gunsel University of Kyrenia Hospital

    RECRUITING

    Kyrenia, Keryneia, 6000, Cyprus

  • Dr. Suat Gunsel University of Kyrenia Hospital

    RECRUITING

    Kyrenia, 6000, Cyprus

More trials for these conditions

Other studies related to the condition(s) this trial covers.